US-based cancer care technology provider Oncology Analytics has closed a $28m series C round featuring representatives of health insurance association Blue Cross Blue Shield and care product supplier McKesson.
Blue Venture Fund and McKesson Ventures joined venture capital and private equity firm Baird Capital, which led the round, and growth equity fund Oak HC/FT.
Founded in 2015, Oncology Analytics has built a data-powered software platform that helps oncology professionals accurately determine cancer treatments such as chemotherapy, radiotherapy and precision medication for patients.
McKesson Ventures, Blue Venture Fund (then known as BlueCross BlueShield Venture Partners) and Oak HC/FT had already taken part in Oncology Analytics’ $21m series B round in late 2018, investing with VC firm Sandbox Industries’ Sandbox Advantage Fund.
BlueCross BlueShield Venture Partners had already a led a $7.5m round for the company in 2016, investing together with Sandbox Advantage Fund.
